REGN Regeneron Pharmaceuticals Inc
Price (delayed)
$625.6
Market cap
$68.39B
P/E Ratio
15.3
Dividend/share
$0.88
EPS
$40.9
Enterprise value
$68.61B
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Tarrytown, New York. The company was founded in 1988. Originally focused on neurotrophic factors and their regenerative capabilities , it
Highlights
REGN's price to earnings (P/E) is 36% lower than its last 4 quarters average of 23.6 and 12% lower than its 5-year quarterly average of 17.2
The equity has grown by 13% year-on-year
Regeneron Pharmaceuticals's net income has increased by 12% YoY but it has decreased by 5% QoQ
The company's EPS rose by 10% YoY but it fell by 5% QoQ
The quick ratio has contracted by 20% YoY and by 11% from the previous quarter
Key stats
What are the main financial stats of REGN
Market
Valuations
Earnings
Shares outstanding
109.32M
Market cap
$68.39B
Enterprise value
$68.61B
Price to earnings (P/E)
15.3
Price to book (P/B)
2.34
Price to sales (P/S)
4.75
EV/EBIT
14.19
EV/EBITDA
12.9
EV/Sales
4.83
Revenue
$14.2B
Gross profit
$12.23B
Operating income
$3.99B
Net income
$4.41B
EBIT
$4.84B
EBITDA
$5.32B
Free cash flow
$3.68B
Per share
Balance sheet
Liquidity
EPS
$40.9
EPS diluted
$38.34
Free cash flow per share
$34.15
Book value per share
$267.12
Revenue per share
$131.62
TBVPS
$339.3
Total assets
$37.76B
Total liabilities
$8.41B
Debt
$2.7B
Equity
$29.35B
Working capital
$14.72B
Debt to equity
0.09
Current ratio
4.73
Quick ratio
3.86
Net debt/EBITDA
0.04
Margins
Efficiency
Dividend
EBITDA margin
37.4%
Gross margin
86.1%
Net margin
31.1%
Operating margin
28.1%
Return on assets
12.1%
Return on equity
15.5%
Return on invested capital
15.1%
Return on capital employed
14.3%
Return on sales
34%
Dividend yield
0.14%
DPS
$0.88
Payout ratio
2.2%
REGN stock price
How has the Regeneron Pharmaceuticals stock price performed over time
Intraday
1.39%
1 week
-2.27%
1 month
-10.47%
1 year
-34.47%
YTD
-12.18%
QTD
-1.36%
Financial performance
How have Regeneron Pharmaceuticals's revenue and profit performed over time
Revenue
$14.2B
Gross profit
$12.23B
Operating income
$3.99B
Net income
$4.41B
Gross margin
86.1%
Net margin
31.1%
Regeneron Pharmaceuticals's net income has increased by 12% YoY but it has decreased by 5% QoQ
Regeneron Pharmaceuticals's operating margin has decreased by 9% YoY and by 2.1% QoQ
Regeneron Pharmaceuticals's gross profit has increased by 8% YoY and by 2.6% from the previous quarter
The revenue has increased by 8% YoY and by 2.6% QoQ
Growth
What is Regeneron Pharmaceuticals's growth rate over time
Valuation
What is Regeneron Pharmaceuticals stock price valuation
P/E
15.3
P/B
2.34
P/S
4.75
EV/EBIT
14.19
EV/EBITDA
12.9
EV/Sales
4.83
REGN's price to earnings (P/E) is 36% lower than its last 4 quarters average of 23.6 and 12% lower than its 5-year quarterly average of 17.2
The company's EPS rose by 10% YoY but it fell by 5% QoQ
REGN's price to book (P/B) is 42% less than its 5-year quarterly average of 4.0 and 38% less than its last 4 quarters average of 3.7
The equity has grown by 13% year-on-year
The P/S is 37% lower than the last 4 quarters average of 7.5 and 26% lower than the 5-year quarterly average of 6.3
The revenue has increased by 8% YoY and by 2.6% QoQ
Efficiency
How efficient is Regeneron Pharmaceuticals business performance
Regeneron Pharmaceuticals's return on equity has decreased by 8% QoQ and by 3.7% YoY
The return on assets has declined by 8% since the previous quarter and by 4% year-on-year
Regeneron Pharmaceuticals's return on invested capital has decreased by 7% QoQ and by 3.8% YoY
The company's return on sales fell by 6% QoQ but it rose by 4.3% YoY
Dividends
What is REGN's dividend history
DPS
$0.88
Dividend yield
0.14%
Payout ratio
2.2%
Recent dividends
Special dividends are included in TTM DPS and yield
Financial health
How did Regeneron Pharmaceuticals financials performed over time
The quick ratio has contracted by 20% YoY and by 11% from the previous quarter
Regeneron Pharmaceuticals's total liabilities has increased by 18% YoY and by 3.6% QoQ
The debt is 91% less than the equity
The equity has grown by 13% year-on-year
REGN's debt to equity is down by 10% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.